Therapeutic inhibition of miR-155 attenuates liver fibrosis via STAT3 signaling

Most chronic liver diseases progress to liver fibrosis, which, when left untreated, can lead to cirrhosis and hepatocellular carcinoma. MicroRNA (miRNA)-targeted therapeutics have become attractive approaches to treat diseases. In this study, we investigated the therapeutic effect of miR-155 inhibit...

Full description

Saved in:
Bibliographic Details
Main Authors: Shashi Bala (Author), Yuan Zhuang (Author), Prashanth Thevkar Nagesh (Author), Donna Catalano (Author), Adam Zivny (Author), Yanbo Wang (Author), Jun Xie (Author), Guangping Gao (Author), Gyongyi Szabo (Author)
Format: Book
Published: Elsevier, 2023-09-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_d75412b366fa4f0f89a90a39beefcc68
042 |a dc 
100 1 0 |a Shashi Bala  |e author 
700 1 0 |a Yuan Zhuang  |e author 
700 1 0 |a Prashanth Thevkar Nagesh  |e author 
700 1 0 |a Donna Catalano  |e author 
700 1 0 |a Adam Zivny  |e author 
700 1 0 |a Yanbo Wang  |e author 
700 1 0 |a Jun Xie  |e author 
700 1 0 |a Guangping Gao  |e author 
700 1 0 |a Gyongyi Szabo  |e author 
245 0 0 |a Therapeutic inhibition of miR-155 attenuates liver fibrosis via STAT3 signaling 
260 |b Elsevier,   |c 2023-09-01T00:00:00Z. 
500 |a 2162-2531 
500 |a 10.1016/j.omtn.2023.07.012 
520 |a Most chronic liver diseases progress to liver fibrosis, which, when left untreated, can lead to cirrhosis and hepatocellular carcinoma. MicroRNA (miRNA)-targeted therapeutics have become attractive approaches to treat diseases. In this study, we investigated the therapeutic effect of miR-155 inhibition in the bile duct ligation (BDL) mouse model of liver fibrosis and evaluated the role of miR-155 in chronic liver fibrosis using miR-155-deficient (miR-155 knockout [KO]) mice. We found increased hepatic miR-155 expression in patients with cirrhosis and in the BDL- and CCl4-induced mouse models of liver fibrosis. Liver fibrosis was significantly reduced in miR-155 KO mice after CCl4 administration or BDL. To assess the therapeutic potential of miR-155 inhibition, we administered an rAAV8-anti-miR-155 tough decoy in vivo that significantly reduced liver damage and fibrosis in BDL. BDL-induced protein levels of transforming growth factor β (TGF-β), p-SMAD2/3, and p-STAT3 were attenuated in anti-miR-155-treated compared with control mice. Hepatic stellate cells from miR-155 KO mice showed attenuation in activation and mesenchymal marker expression. In vitro, miR-155 gain- and loss-of-function studies revealed that miR-155 regulates activation of stellate cells partly via STAT3 signaling. Our study suggests that miR-155 is the key regulator of liver fibrosis and might be a potential therapeutic target to attenuate fibrosis progression. 
546 |a EN 
690 |a MT: Non-coding RNAs 
690 |a anti-miR-155 tough decoy 
690 |a SMAD2/3 
690 |a STAT3 
690 |a CCl4 
690 |a BDL 
690 |a Therapeutics. Pharmacology 
690 |a RM1-950 
655 7 |a article  |2 local 
786 0 |n Molecular Therapy: Nucleic Acids, Vol 33, Iss , Pp 413-427 (2023) 
787 0 |n http://www.sciencedirect.com/science/article/pii/S2162253123001853 
787 0 |n https://doaj.org/toc/2162-2531 
856 4 1 |u https://doaj.org/article/d75412b366fa4f0f89a90a39beefcc68  |z Connect to this object online.